
Sign up to save your podcasts
Or


In this JAMA Author Interview, JAMA Interim Executive Editor Greg Curfman, MD, speaks with Mary M. McDermott, MD, professor of medicine at Northwestern University Feinberg School of Medicine, on current therapies for peripheral artery disease and a new clinical trial she directed on the use of telmisartan, an angiotensin receptor blocker, for patients with peripheral artery disease.
Related Content:
Effect of Telmisartan on Walking Performance in Patients With Lower Extremity Peripheral Artery Disease
By JAMA Network4.6
162162 ratings
In this JAMA Author Interview, JAMA Interim Executive Editor Greg Curfman, MD, speaks with Mary M. McDermott, MD, professor of medicine at Northwestern University Feinberg School of Medicine, on current therapies for peripheral artery disease and a new clinical trial she directed on the use of telmisartan, an angiotensin receptor blocker, for patients with peripheral artery disease.
Related Content:
Effect of Telmisartan on Walking Performance in Patients With Lower Extremity Peripheral Artery Disease

38,513 Listeners

43,656 Listeners

27,021 Listeners

133 Listeners

320 Listeners

542 Listeners

706 Listeners

501 Listeners

6,444 Listeners

298 Listeners

266 Listeners

3,387 Listeners

21 Listeners

15 Listeners

7 Listeners

7 Listeners

19 Listeners

30 Listeners

90 Listeners

520 Listeners

367 Listeners

18 Listeners

375 Listeners